ERN1 and atherosclerosis: IRE1 inhibitors STF-083010 and 4μ8C suppress lipid-triggered mitochondrial ROS release, NLRP3 inflammasome activation, production of IL-1 and IL-18 and thus retarding the progression of atherosclerosis in ApoE−/− mice [111].